KMDA Kamada Ltd.
5.41
-0.04 -1%
Previous Close
5.45
Open
5.44
Price To Book
1.85
Market Cap
217,996,372
Shares
40,295,078
Volume
18,552
Short Ratio
Av. Daily Volume
96,805
NewsSee all news
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Alpha-1 antitrypsin (AAT)
Prevention of lung transplant rejection
Approval announced August 25, 2017.
KamRAB
Prophylaxis of rabies disease
Phase 3 trial planned for 2H 2019.
Inhaled formulation of AAT
AATD - Alpha-1 Antitrypsin deficiency
Phase 2 data released November 3, 2017. No significant treatment effect noted overall.
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
Latest News
- Kamada Ltd. (KMDA) Q1 2019 Earnings Call Transcript
- Kamada (KMDA) Tops Q1 Earnings and Revenue Estimates
- Kamada: 1Q Earnings Snapshot
- Kamada Reports Financial Results for First Quarter of 2019
- Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?
- A Preview Of Kamada's Q1 Earnings
- Kamada (KMDA) Stock Moves -1.05%: What You Should Know
- Kamada to Report First Quarter 2019 Financial Results and Host Conference Call on May 14
- Kamada (KMDA) Gains As Market Dips: What You Should Know
- Is Kamada (KMDA) Stock Outpacing Its Medical Peers This Year?
- Kamada to Begin Phase III Study for Inhaled AAT Product in 2H
- Kamada announces FDA acceptance of Inhaled AAT program path forward
- 5 Stocks With Increasing Cash Flows to Scoop Up Big Gains
- Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest
- Acorda to Gain From Inbrija Sales and Neurological Pipeline
- BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M
- Kamada (KMDA) Stock Sinks As Market Gains: What You Should Know
- Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin
- PhaseBio Stock Up on Breakthrough Therapy Status for PB2452